CD8A and neoplasm: As such, several ongoing studies are currently assessing the immunomodulatory potential of combining anti-angiogenic agents with immunotherapy and chemotherapy, and preliminary results are promising.In a trial on metastatic melanoma patients being treated with the either Ipilimumab alone or a combination of Bevacizumab and Ipilimumab, the addition of Bevacizumab in the second arm resulted in a remarkable increase in tumor-infiltrating CD8+ T-cell as compared to the first arm [181].